Harbour BioMed and Pharmaceutical Product Development, LLC (PPD) entered a strategic collaboration to develop HBM’s therapeutics in the fields of oncology and immunology.   HBM and PPD recently completed an Australian ethics committee (EC) submission for HBM4003, an anti-cancer immunotherapyto target solid tumors. The companies achieved the key milestone ahead of schedule, on the path to Phase I trials in Australia and the U.S.    “As a rapidly growing, medium-sized biotech company with glob...